Mikio Shoji
Maebashi, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 62 publications
Drebrin is a novel biomarker of cognitive deterioration in Alzheimer's disease.
Journal: Journal of Alzheimer's disease : JAD
Published: January 02, 2026
Clinical Validation of Plasma p-217tau in Neurological Diseases.
Journal: Annals of clinical and translational neurology
Published: November 25, 2025
18F-FDG PET for the differential diagnosis of Alzheimer's disease and frontotemporal lobar degeneration: A multicenter prospective study in Japan.
Journal: Journal of Alzheimer's disease : JAD
Published: May 06, 2025
A case of the iatrogenic transmission of vascular Aß40 amyloid.
Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
Published: October 29, 2024
A case of fragile X-associated tremor/ataxia syndrome with superior cerebellar peduncle lesions.
Journal: eNeurologicalSci
Published: July 05, 2024
High levels of plasma neurofilament light chain correlated with brainstem and peripheral nerve damage.
Journal: Journal of the neurological sciences
Published: May 27, 2024
A Longitudinal Study of CogEvo's Prediction of Cognitive Decline in Older Adults.
Journal: Healthcare (Basel, Switzerland)
Published: April 29, 2024
Clinical Evaluation of Cerebrospinal Fluid p217tau and Neurofilament Light Chain Levels in Patients with Alzheimer's Disease or Other Neurological Diseases.
Journal: Journal of Alzheimer's disease : JAD
Published: November 26, 2023
Relation of leg phase angle from bioelectrical impedance analysis with voluntary and evoked contractile properties of the plantar flexors.
Journal: Frontiers in physiology
Published: September 12, 2023
A case of chronic progressive autoimmune GFAP astrocytopathy with extensive meningoencephalomyelitis and contrast enhancement on MRI.
Journal: eNeurologicalSci
Published: August 26, 2023
Plasma ApoE4 Levels Are Lower than ApoE2 and ApoE3 Levels, and Not Associated with Plasma Aβ40/42 Ratio as a Biomarker of Amyloid-β Amyloidosis in Alzheimer's Disease.
Journal: Journal of Alzheimer's disease : JAD
Published: March 27, 2023
Annual stability of the plasma Aß40/42 ratio and associated factors.
Journal: Annals of clinical and translational neurology
Published: December 13, 2022
Last Updated: 09/26/2026